Aligning Access with Outcomes for Early-Stage Alzheimer’s Disease Drugs
Contact InformationSarah Supsiri
A number of innovative “early stage” Alzheimer’s disease (AD) therapies are currently under development. These therapies may enable interception of disease progression long before irreversible symptoms develop, and coupled with diagnostics that identify disease at earlier stages, hold the promise of slowing or even stopping disease progression. However, reimbursement through traditional payment models may raise concerns about high upfront and chronic treatment costs, leading to questions about return on investment, coverage, and access. Shifting the payment structure to value-based payments (VBP), where reimbursement is correlated to outcome measures, may help mitigate some of the uncertainties associated with these drugs. This workshop will consider approaches to delineate appropriate patient populations, establish evidence or outcome measures that are an appropriate fit for the technology, and develop a strategy that enables data collection and analysis.